摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R,4R,5S)-ethyl 4-amino-5-(tert-butoxycarbonylamino)-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate | 1012814-35-5

中文名称
——
中文别名
——
英文名称
(3R,4R,5S)-ethyl 4-amino-5-(tert-butoxycarbonylamino)-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate
英文别名
(3R,4R,5S)-ethyl 4-amino-5-(tert-butoxycarbonylamino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate;ethyl (3R,4R,5S)-4-amino-5-[(2-methylpropan-2-yl)oxycarbonylamino]-3-pentan-3-yloxycyclohexene-1-carboxylate
(3R,4R,5S)-ethyl 4-amino-5-(tert-butoxycarbonylamino)-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate化学式
CAS
1012814-35-5
化学式
C19H34N2O5
mdl
——
分子量
370.489
InChiKey
BEUDGGBCHPAZFY-ARFHVFGLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    51-52 °C
  • 沸点:
    475.1±45.0 °C(Predicted)
  • 密度:
    1.08±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    26
  • 可旋转键数:
    10
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.79
  • 拓扑面积:
    99.9
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • The first synthesis of [<sup>11</sup>C]oseltamivir: a tool for elucidating the relationship between Tamiflu and its adverse effects on the central nervous system
    作者:Takuya Arai、Fujiko Konno、Masanao Ogawa、Ming-Rong Zhang、Kazutoshi Suzuki
    DOI:10.1002/jlcr.1604
    日期:2009.7
    Oseltamivir phosphate (Tamiflu®) is an anti-influenza drug approved in many countries. Recently, in Japan, adverse effects on the central nervous system have been reported in younger patients administrated with Tamiflu. As a tool for elucidating the relationship between Tamiflu and its adverse effects, 11C-labeled oseltamivir was synthesized through a two-step reaction involving [11C]acetylation with [1-11C]acetyl chloride. Starting from approximately 37.0 GBq of [11C]CO2, 1.2–1.8 GBq (n=5) of [11C]oseltamivir was obtained at the end of synthesis (EOS) 36–39 min after the end of bombardment. Radiochemical purity and specific activity were greater than 98% and 2.7–6.3 GBq/µmol at EOS, respectively. Copyright © 2009 John Wiley & Sons, Ltd.
    磷酸奥司他韦(达®)是一种在许多国家获批的抗流感药物。最近,在日本,有报道称年轻患者在使用达后出现了中枢神经系统的副作用。为了阐明达与其副作用之间的关系,通过两步反应合成11C标记的奥司他韦,其中包括用[1-11C]乙酰氯进行[11C]乙酰化。从大约37.0 GBq的[11C]CO2开始,合成的最后阶段(EOS)在轰击结束后的36-39分钟内获得了1.2-1.8 GBq(n=5)的[11C]奥司他韦。在EOS时,放射化学纯度和比活性分别大于98%和2.7-6.3 GBq/µmol。版权所有 © 2009 John Wiley & Sons, Ltd.
  • New, Efficient Synthesis of Oseltamivir Phosphate (Tamiflu) via Enzymatic Desymmetrization of a <i>meso</i>-1,3-Cyclohexanedicarboxylic Acid Diester
    作者:Ulrich Zutter、Hans Iding、Paul Spurr、Beat Wirz
    DOI:10.1021/jo800264d
    日期:2008.7.1
    resultant all-cis meso-diesters 7a and 7b, respectively. Enzymatic hydrolysis of the meso-diester 7b with pig liver esterase afforded the (S)-monoacid 8b, which was converted into cyclohexenol 17 via a Curtius degradation and a base-catalyzed decarboxylative elimination of the Boc-protected oxazolidinone 14. Introduction of the second amino function via SN2 substitution of the corresponding triflate 18 with
    流感神经氨酸酶抑制剂的前药的磷酸奥司他韦的一个新的,对映选择性合成1(达)及其对映体ENT -1从开始便宜,可商购的2,6-二甲氧基苯酚10进行说明。该方法的主要特征包括5-(1-乙基-丙氧基)-4,6-二甲氧基间苯二甲酸二乙酯(6a)的顺式加氢和所得全顺式内消旋二酯7a和7b的脱对称化。, 分别。用猪肝酯酶酶促内消旋二酯7b解得到(S)-单酸参见图8b,其通过Curtius降解和Boc保护的恶唑烷酮14的碱催化的脱羧消除而转化成环己烯17。通过用NaN 3取代相应的三氟甲磺酸18的S N 2引入第二个基官能团,然后进行叠氮化物还原,N-乙酰化和Boc脱保护,总共10步产生了奥司他韦磷酸酯1,总收率约为30% 。对映异构体ENT -1经由的酶促desymmetrization类似地获得内消旋-diester 7A与米曲霉的脂肪酶,从而提供([R)-monoacid ENT -8A。
  • Fluorosubstituted-(3R,4R,5S)-5-guanidino 4-acetamido-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid compound, ester and use thereof
    申请人:ASAVI, LLC
    公开号:US20130303609A1
    公开(公告)日:2013-11-14
    The present invention relates to novel neuraminidase activity inhibitors and use thereof for prophylaxis and treatment of influenza infection, that is to fluorosubstituted4-acetamido-5-guanidino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acids and their esters of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, wherein R is hydrogen, an optionally substituted C 1 -C 5 alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl; Rf is CH 2 F or CHF 2 . A pharmaceutical composition is provided, a method for its preparation, as well as a method for prophylaxis and treatment of viral diseases.
    本发明涉及新型神经氨酸酶活性抑制剂及其在预防和治疗流感感染中的用途,即取代的4-乙酰胺基-5-基-3-(戊-3-氧基)环己-1-烯羧酸及其一般式1的酯,其药学上可接受的盐和/或合物,其中R为氢,可选择地取代的C1-C5烷基,C2-C5烯基或C2-C5炔基;Rf为CH2FCHF2。提供了一种药物组合物,以及其制备方法,以及预防和治疗病毒性疾病的方法。
  • Radiosyntheses of two positron emission tomography probes: [11C]Oseltamivir and its active metabolite [11C]Ro 64-0802
    作者:Fujiko Konno、Takuya Arai、Ming-Rong Zhang、Akiko Hatori、Kazuhiko Yanamoto、Masanao Ogawa、Gukuto Ito、Chika Odawara、Tomoteru Yamasaki、Koichi Kato、Kazutoshi Suzuki
    DOI:10.1016/j.bmcl.2008.01.037
    日期:2008.2
    Oseltamivir phosphate (Tamiflu (R), 1:H3PO4 is an orally active anti-influenza drug, which is hydrolyzed by esterase to its carboxylate metabolite Ro 64-0802 ( 2) with potent activity inhibiting neuraminidase. In this study, for the first time, we synthesized carbon-11-labeled oseltamivir ([C-11]1) and Ro 64- 0802 ([C-11] 2) as two novel positron emission tomography probes and demonstrated that [C-11] 1 had twofold higher radioactivity concentration in the mouse brains than [C-11]2. (c) 2008 Elsevier Ltd. All rights reserved.
  • A method for the synthesis of an oseltamivir PET tracer
    作者:Masataka Morita、Toshihiko Sone、Kenzo Yamatsugu、Yoshihiro Sohtome、Shigeki Matsunaga、Motomu Kanai、Yasuyoshi Watanabe、Masakatsu Shibasaki
    DOI:10.1016/j.bmcl.2007.11.079
    日期:2008.1
    A protocol applicable for the synthesis of an oseltamivir positron emission tomography (PET) tracer was developed. Acetylation of amine 3 with CH3COCl, followed by deprotection and aqueous workup, produced oseltamivir 4 from 3 within 10 min. The obtained 4 was sufficiently pure for PET studies. This method can be extended to PET tracer synthesis using (CH3COCl)-C-11. (c) 2007 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸